CSL Behring Helps Fuel Switzerland’s Fertile Innovation Ecosystem

Known for our life-changing biotherapies, CSL Behring is one of a number of companies that benefit from the Swiss model of vocational education.

Lernende%20(3)[1]

By Jasmin Joller

December 22, 2016

At our manufacturing facility in Bern, we’ve been receiving visits from dignitaries and business heads from around the world such as U.S. Secretary of Labor Thomas E. Perez, President of Poland Andrzej Duda, Microsoft President Brad Smith and the European-Australian Business Council.

Usually we attract attention because of our world-class biotherapies, or because we’ve been recognized as an employer of choice in Switzerland. Now we’re attracting attention because it’s widely recognized that Switzerland has set quite a standard for occupational learning programs, and CSL Behring is a shining example of that standard.

Continue reading

FacebookTwitterGoogle+EmailShare

Working Each Day As If People’s Lives Depend on Us

At CSL Behring, a Job Isn’t Just a Job

Recruitment #4
(Photo by Patrick Fore)

By Elizabeth Walker

I’m often asked, “What makes CSL Behring a great place to work?” For me, it’s about our patient centricity and company purpose. We develop and deliver innovative specialty biotherapies, helping people with life-threatening conditions live full lives. That’s an inspiring responsibility. Our CEO Paul Perreault encourages us to work each day as if people’s lives depend on us ‒ because they do. I can’t think of a better reason for coming to work every day.

Continue reading

What Will Healthcare Look Like in 50 to 100 Years?

If we focus on innovation and sustainability, healthcare will evolve in ways that are in sync with the changing needs of patients, the economy and global politics.

BioFest 2016

The following post is excerpted from Paul Perreault’s remarks at International BioFest 2016 in Melbourne, Australia.

December 6, 2016

Healthcare statisticians tell us that the first person who will live to 150 years of age has already been born. Considering human biology and the challenges we would need to overcome, doubling our life expectancy at first seems fanciful. But with our understanding of science and the refined art of personalized medicine, 150 may be reasonable.

In fact, our understanding of human biology is expanding at an exponential rate. Ten years ago it took the world’s greatest minds 10 years to map the human genome. Now it takes one day. Even for those of us in the healthcare sector, it is virtually impossible to predict what healthcare will look like in 50 or 100 years. But there are constants to guide us.

Continue reading

Coagulation Research Award Taps Brain Power and Vision of New Generation of Researchers

The CSL Behring Professor Heimburger Award is helping to ensure young researchers around the world have the opportunity to bring their innovative ideas to the forefront.

October 1­­7, 2016

 

We are seeing some exciting research as CSL Behring delivers on our promise to advance research and innovation through grants such as the Heimburger Award.

This is particularly important for young researchers working in clinics who often don’t have time to raise money for their research. Adding to the challenge is the fact that government funding of orphan disease research is often difficult to obtain.

Without Human Plasma, Many Patients with Rare and Serious Medical Disorders Would Not Have Treatments Available to Them

That’s why plasma donors are heroes to millions of patients who receive plasma-derived therapies.

October ­­7, 2016
By Daniel Ferris

Barb and Rusty Roberts

Immune deficiency patient Barb Roberts with Rusty Roberts vacationing in Dinard, France.

Every autumn the plasma protein therapeutics industry recognizes the lifesaving contributions of plasma donors during International Plasma Awareness Week (IPAW).

At CSL Behring and CSL Plasma, we appreciate the critical role donors play in ensuring a reliable and secure source of human plasma as worldwide demand continues to rise. We value their donations not just during IPAW (October 9-15), but year-round.

This is because plasma-derived therapies are crucial for patients’ well-being and health, and an appropriate supply of products is absolutely essential and depends on a sufficient supply of collected plasma.  

While it can take more than 1,000 plasma donations to treat one adult patient for a year, the current collection system allows for an appropriate supply of product.
Continue reading

Posts represent the opinion of the author and do not necessarily reflect the views of CSL Behring.
This site is not intended as a forum for discussing CSL Behring or other companies' products.
Comments on this blog may be reviewed by CSL Behring and may be subject to removal if they are deemed to have inappropriate content.